KSC · 207940.KS
Samsung Biologics Co.,Ltd.
₩1,487,000+₩121,000 (+8.86%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.16% below the high.
Loading market information…
KOE · 086900.KQ · KRW
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Medy-Tox Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Medy-Tox Inc.’s forward annual dividend is ₩1,200 per share, paid annual. The forward yield is 1.88% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Medy-Tox Inc.’s next earnings report is currently expected on Nov 16, 2026, with estimated earnings per share of ₩816. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Medy-Tox Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Medy-Tox Inc., a biopharmaceutical company established in 2000 and headquartered in Cheongju, South Korea, develops and distributes a diverse array of medical products. Its offerings include several botulinum toxin treatments: Neuronox, a lyophilized injectable powder, which is utilized for treating foot deformities caused by spasticity in children with cerebral palsy; INNOTOX, a transparent liquid injectable solution aimed at the temporary improvement of moderate to severe glabellar wrinkles; and Coretox, another freeze-dried injectable powder, also formulated for temporarily reducing moderate to severe frown lines. The company also manufactures hyaluronic acid-based dermal fillers, such as Neuramis and Potenfill, which function as tissue-recovering biomaterials. Beyond injectables, Medy-Tox provides various medical devices, including ComfortDual and Recell Ice, designed for tissue coagulation using high-frequency current; Neurajet Plus, an assisting tool for administering other pharmaceuticals; Carewave, which employs low-intensity electromagnetic shockwaves to address erectile dysfunction; and Careveam, an ultraviolet light device for managing skin ailments. Furthermore, the company offers Neurakin cream, a topical treatment for a range of dermatological conditions including acute and chronic eczema, contact and atopic dermatitis, rosacea and perioral dermatitis, herpes zoster, and acne vulgaris. Medy-Tox's products are exported to approximately 60 countries worldwide, with key markets encompassing Japan, Thailand, and Brazil. The company is also collaborating with Dyadic International, Inc. to develop vaccines targeting COVID-19 variants.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:39 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2024 | Mar 13, 2025 | ₩451-64.68% vs estimate | ₩55.2B-7.9% vs estimate |
|---|
| Q3 2024 | Nov 11, 2024 | ₩566-82.57% vs estimate | ₩53.9B0.0% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩1,487,000+₩121,000 (+8.86%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.16% below the high.
₩191,600+₩2,300 (+1.22%)
Celltrion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.85% below the high.
₩211,500-₩8,500 (-3.86%)
Alteogen Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.68% below the high.
₩309,500+₩2,500 (+0.81%)
Samsung Epis Holdings’s quoted price sits in the lower half of its reported 52-week range, 59.96% below the high.
₩179,800-₩3,500 (-1.91%)
Hugel, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.72% below the high.
₩5,860-₩60 (-1.01%)
JETEMA, Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.05% below the high.
₩2,350-₩80 (-3.29%)
BNC Korea Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 61.97% below the high.
₩5,020-₩40 (-0.79%)
DongBang Medical’s quoted price sits in the lower half of its reported 52-week range, 48.03% below the high.
